OncoPharm

Latest Episodes:

HER2 Mutated NSCLC Aug 18, 2022

Show notes

In light of trastuzumab deruxtecan's approval for HER-mutated NSCLC, it's worthwhile to look back at the history of HER-targeted therapy in NSCLC and why/how targeted HER-mutated disease will affect practice.

Updated Adjuvant Atezolizumab Data (& more) Aug 11, 2022

Show notes

New OS data is out for adjuvant atezolizumab in NSCLC - how does it compare to the original DFS data? Plus, lots of recent FDA expanded approvals to discuss.

The Infamous Erlotinib Study Aug 04, 2022

Show notes

An infamous study that led to a drug approval of limited benefit, but still made its way into an episode of Better Call Saul. Erlotinib + gemcitabine vs. gemcitabine: https://doi.org/10.1200/jco.2006.07.9525

Long Term Follow-Up Jul 28, 2022

Show notes

Several recent large trials just released long term follow-up results on overall survival. We look at what how treatment principles may change based on these mature data. ECHELON-1 - Hodgkin's (A+AVD vs. ABVD) POLO - Pancreatic (olaparib maintenance vs. placebo) Keynote 355 - mTNBC (pembrolizumab + chemo vs. chemo) APHinity - adjuvant HER+ breast (pertuzumab/trastuzumab vs. trastuzumab) E1912 - CLL (ibrutinib/rituximab vs. FCR)

Living With Lupus Jul 14, 2022

Show notes

Discussion with a Lupus Nephritis patient (and Pharm.D. student) about manifestations and treatments of SLE and Lupus Nephritis.

ICIs & PPIs - Something to Worry About? Jul 07, 2022

Show notes

Sifting through and summarizing lots of data on concomitant use of ICIs and PPIs. Suggested readings: 1. All the drugs: https://pubmed.ncbi.nlm.nih.gov/33154150/ 2. Pooled atezolizumab study: https://pubmed.ncbi.nlm.nih.gov/35183773/ 3. Clostridium butyricum may be a thing: https://pubmed.ncbi.nlm.nih.gov/35655708/ 4. AKI risk: https://doi.org/10.21873/invivo.12570 5. Is this all noise?: https://pubmed.ncbi.nlm.nih.gov/35280736/ 6. Abx & PPIs: https://doi.org/10.3389/fimmu.2021.716317

APAP + ICI: An emerging concern? Jun 30, 2022

Show notes

Acetaminophen (or paracetamol) & immune checkpoint inhibitors are ubiquitous in oncology practices. So, when new translational research suggests APAP may decrease the effectiveness - well that seems like something worth talking about. Impact of acetaminophen on the efficacy of immunotherapy in cancer patients: https://doi.org/10.1016/j.annonc.2022.05.010 Hepatotoxicity risk factors with ICIs: https://doi.org/10.1097/cji.0000000000000347

FN Updates Jun 23, 2022

Show notes

Febrile neutropenia updates on... Short duration antibiotics: https://doi.org/10.1016/S2352-3026(22)00145-4 Same-day pegfilgrastim: https://doi.org/10.2217/fon-2022-0365

LGBTQ Clinical Pearls Jun 16, 2022

Show notes

Maya Leiva, PharmD, BCOP joins the Pod once again this Pride month to give us some LGBTQ clinical pearls on carboplatin dosing in trans patients and pregnancy/teratogenicity chemo counseling. LGBT Cancer Network: https://cancer-network.org

ASCO 2022 Highlights Jun 09, 2022

Show notes

Highlights from ASCO's 2022 annual meeting.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected